JP2023543763A - バイオマーカー - Google Patents

バイオマーカー Download PDF

Info

Publication number
JP2023543763A
JP2023543763A JP2023518817A JP2023518817A JP2023543763A JP 2023543763 A JP2023543763 A JP 2023543763A JP 2023518817 A JP2023518817 A JP 2023518817A JP 2023518817 A JP2023518817 A JP 2023518817A JP 2023543763 A JP2023543763 A JP 2023543763A
Authority
JP
Japan
Prior art keywords
subject
nafld
foxo1
arld
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518817A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022064198A5 (https=
JP2023543763A5 (https=
Inventor
マシュー ホーア
ピーター キャンベル
スタンレー エヌジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Genome Research Ltd
Original Assignee
Cambridge Enterprise Ltd
Genome Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd, Genome Research Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2023543763A publication Critical patent/JP2023543763A/ja
Publication of JPWO2022064198A5 publication Critical patent/JPWO2022064198A5/ja
Publication of JP2023543763A5 publication Critical patent/JP2023543763A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023518817A 2020-09-23 2021-09-23 バイオマーカー Pending JP2023543763A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2015056.1 2020-09-23
GBGB2015056.1A GB202015056D0 (en) 2020-09-23 2020-09-23 Biomarkers
PCT/GB2021/052469 WO2022064198A1 (en) 2020-09-23 2021-09-23 Biomarkers

Publications (3)

Publication Number Publication Date
JP2023543763A true JP2023543763A (ja) 2023-10-18
JPWO2022064198A5 JPWO2022064198A5 (https=) 2024-09-27
JP2023543763A5 JP2023543763A5 (https=) 2024-09-27

Family

ID=73139042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518817A Pending JP2023543763A (ja) 2020-09-23 2021-09-23 バイオマーカー

Country Status (6)

Country Link
US (1) US20230348983A1 (https=)
EP (1) EP4217507A1 (https=)
JP (1) JP2023543763A (https=)
CN (1) CN116867910A (https=)
GB (1) GB202015056D0 (https=)
WO (1) WO2022064198A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250028934A1 (en) * 2023-07-17 2025-01-23 The Toronto-Dominion Bank Systems and methods for time series prediction using multi-stage computation
US20250263702A1 (en) * 2024-02-19 2025-08-21 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting cideb and related methods
WO2025230979A1 (en) * 2024-04-30 2025-11-06 Flagship Pioneering Innovations Vii, Llc Tnfaip3-targeted compositions and related methods
WO2026038054A2 (en) * 2024-08-15 2026-02-19 Genome Research Limited Novel companion diagnostic method

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526482A (ja) * 2008-07-03 2011-10-13 サンタリス ファーマ アー／エス ミトコンドリアグリセロール−３−リン酸アシルトランスフェラーゼ１（ｍｔｇｐａｔ１）の発現を阻害するためのｒｎａアンタゴニスト化合物
JP2016063813A (ja) * 2009-09-11 2016-04-28 ザ チャイニーズ ユニバーシティ オブ ホンコン 肝臓病変を評価する方法
JP2018169277A (ja) * 2017-03-29 2018-11-01 国立大学法人神戸大学 炎症性関連病態を伴う非アルコール性脂肪性肝疾患のバイオマーカー
WO2019234779A1 (en) * 2018-06-08 2019-12-12 Ospedale Pediatrico Bambino Gesu' Use of snp rs17618244 as a predictive marker in nonalcoholic fatty liver disease (nafld)
WO2020044497A1 (ja) * 2018-08-30 2020-03-05 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
JP2020527716A (ja) * 2017-07-19 2020-09-10 バイオ—ラッド ヨーロッパ ゲーエムベーハー 非アルコール性脂肪性肝炎及び肝線維症ステータスを同時に評価するバイオマーカの組み合わせ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526482A (ja) * 2008-07-03 2011-10-13 サンタリス ファーマ アー／エス ミトコンドリアグリセロール−３−リン酸アシルトランスフェラーゼ１（ｍｔｇｐａｔ１）の発現を阻害するためのｒｎａアンタゴニスト化合物
JP2016063813A (ja) * 2009-09-11 2016-04-28 ザ チャイニーズ ユニバーシティ オブ ホンコン 肝臓病変を評価する方法
JP2018169277A (ja) * 2017-03-29 2018-11-01 国立大学法人神戸大学 炎症性関連病態を伴う非アルコール性脂肪性肝疾患のバイオマーカー
JP2020527716A (ja) * 2017-07-19 2020-09-10 バイオ—ラッド ヨーロッパ ゲーエムベーハー 非アルコール性脂肪性肝炎及び肝線維症ステータスを同時に評価するバイオマーカの組み合わせ
WO2019234779A1 (en) * 2018-06-08 2019-12-12 Ospedale Pediatrico Bambino Gesu' Use of snp rs17618244 as a predictive marker in nonalcoholic fatty liver disease (nafld)
WO2020044497A1 (ja) * 2018-08-30 2020-03-05 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRUNNER, SIMON F. ET AL.: "Somatic mutations and clonal dynamics in healthy and cirrhotic human liver", NATURE, vol. 574, no. 7779, JPN6025038313, 23 October 2019 (2019-10-23), pages 538 - 542, ISSN: 0005688137 *
PING, FAN ET AL.: "Deoxyribonucleic acid telomere length shortening can predict the incidence of non‐alcoholic fatty l", JOURNAL OF DIABETES INVESTIGATION, vol. 8, no. 2, JPN6025038312, 30 August 2016 (2016-08-30), pages 174 - 180, ISSN: 0005688138 *
VALENTI, L. ET AL.: "726 GENOTYPE OF THE TRANSCRIPTION FACTOR FOXO1 MEDIANTING INSULIN SIGNALING INFLUENCES THE SUSCEPTIB", JOURNAL OF HEPATOLOGY, vol. 50, JPN6025038314, April 2009 (2009-04-01), pages 265, ISSN: 0005688136 *

Also Published As

Publication number Publication date
EP4217507A1 (en) 2023-08-02
WO2022064198A1 (en) 2022-03-31
US20230348983A1 (en) 2023-11-02
GB202015056D0 (en) 2020-11-04
CN116867910A (zh) 2023-10-10

Similar Documents

Publication Publication Date Title
Ng et al. Convergent somatic mutations in metabolism genes in chronic liver disease
Olafsson et al. Somatic evolution in non-neoplastic IBD-affected colon
Huang et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer
CN110305965B (zh) 一种预测非小细胞肺癌（nsclc）患者对免疫疗法的敏感性的方法
JP7340021B2 (ja) 予測腫瘍遺伝子変異量に基づいた腫瘍分類
JP2023543763A (ja) バイオマーカー
Tong et al. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
JP6704861B2 (ja) 癌処置のための個別化三剤治療を選択するための方法
Stanta et al. Tumour heterogeneity: principles and practical consequences
Chen et al. Genetic profile of non‐small cell lung cancer (NSCLC): A hospital‐based survey in Jinhua
JP2022505295A (ja) ヒト腫瘍のがん細胞における分子活性を定量化するための方法
Zhang et al. Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
AU2019250606A1 (en) Improved classification and prognosis of prostate cancer
Hynds et al. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Aung et al. Spatially informed gene signatures for response to immunotherapy in melanoma
Boons et al. Clinical applications of (epi) genetics in gastroenteropancreatic neuroendocrine neoplasms: moving towards liquid biopsies
Durso et al. Aberrant methylation patterns in colorectal cancer: a meta-analysis
Xu et al. Comprehensive analysis of the expression and prognosis for S100 in human ovarian cancer: A STROBE study
Garziera et al. Clonal evolution of TP53 c. 375+ 1G> A mutation in pre-and post-neo-adjuvant chemotherapy (NACT) tumor samples in high-grade serous ovarian cancer (HGSOC)
Cheng et al. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer
Yang et al. Prognostic and predictive impact of molecular tumor burden index in non‐small cell lung cancer patients
WO2019157470A1 (en) Bam signatures from liquid and solid tumors and uses therefor
CN110004229A (zh) 多基因作为egfr单克隆抗体类药物耐药标志物的应用
Yang et al. Single nucleotide polymorphisms rs148582811 regulates its host gene ARVCF expression to affect nicotine-associated hippocampus-dependent memory
Yang et al. SPOP expression is associated with tumor-infiltrating lymphocytes in pancreatic cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240918

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260414